Page 665 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 29 Tumors of the Male Reproductive System 643

261. Mottet N, Bellmunt J, Bolla M, et al.: EAU-ESTRO-SIOG guide- 278. James ND, de Bono JS, Spears MR, et al.: Abiraterone for prostate
lines on prostate cancer. part 1: screening, diagnosis, and local cancer not previously treated with hormone therapy, N Eng J Med
treatment with curative intent, Eur Urol 71:618–629, 2017. 377:338–351, 2017.
VetBooks.ir 262. Jeldres C, Cullen J, Hurwitz LM, et al.: Prospective quality-of-life 279. Cornford P, Bellmunt J, Bolla M, et al.: EAU-ESTRO-SIOG
Guidelines on prostate cancer. Part II: treatment of relapsing, met-
outcomes for low-risk prostate cancer: active surveillance versus
radical prostatectomy, Cancer 121:2465–2473, 2015.
263. Punnen S, Cowan JE, Chan JM, et al.: Long-term health- astatic, and castration-resistant prostate cancer, Eur Urol 71:630–
642, 2017.
related quality of life after primary treatment for localized pros- 280. Michels GM, Knapp DW, David M, et al.: Penile prolapse and
tate cancer: results from the CaPSURE registry, Eur Urol 68: urethral obstruction secondary to lymphosarcoma of the penis in a
600–608, 2015. dog, J Am An Hosp Assoc 37:474–477, 2001.
264. Banerji JS, Hurwitz LM, Cullen J, et al.: A prospective study of 281. Cornegliani L, Vercelli A, Abramo F: Idiopathic mucosal penile
health-related quality-of-life outcomes for patients with low-risk squamous papillomas in dogs, Vet Dermatol 18:439–443, 2007.
prostate cancer managed by active surveillance or radiation ther- 282. Ndiritu CG: Lesions of the canine penis and prepuce, Mod Vet
apy, Urol Oncol 35:234–242, 2017. Pract 60:712–715, 1979.
265. Chistiakov DA, Myasoedova VA, Grechko AV, et al.: New bio- 283. Patnaik AK, Matthiesen DT, Zawie DA: Two cases of canine penile
markers for diagnosis and prognosis of localized prostate can- neoplasm: squamous cell carcinoma and mesenchymal chondrosar-
cer, Semin Cancer Biol, 2018, epub ahead of print. https://doi. coma, J Am An Hosp Assoc 24:403–406, 1988.
org/10.1013/j.semcancer.2018.2018.01.012. 284. Hall WC, Nielsen SW, McEntee K: Tumours of the prostate and
266. Friedl A, Stangl K, Bauer W, et al.: Prostate-specific antigen param- penis, Bull World Health Organ 53:247–256, 1976.
eters and prostate health index enhance prostate cancer prediction 285. Bloom F: Pathology of the dog and cat: the genitourinary system with
with the in-bore 3-T magnetic resonance imaging-guided transrec- clinical considerations, Evanston, 1954, American Veterinary Publi-
tal targeted prostate biopsy after negative 12-core biopsy, Urology cations.
110:148–153, 2017. 286. Vascellari M, Carminato A, Camali G, et al.: Malignant meso-
267. Druskin SC, Tosoian JJ, Young A, et al.: Combining prostate thelioma of the tunica vaginalis testis in a dog: histological and
health index density, magnetic resonance imaging and prior nega- immunohistochemical characterization, J Vet Diagn Invest 23:
tive biopsy status to improve the detection of clinically significant 135–139, 2011.
prostate cancer, BJU Int 121:619–626, 2018. 287. Cihak RW, Roen DR, Klaassen J: Malignant mesothelioma of the
268. Campi R, Brookman-May SD, Subiela Henriquez JD, et al.: tunica vaginalis in a dog, J Comp Pathol 96:459–462, 1986.
Impact of metabolic diseases, drugs, and dietary factors on pros- 288. Peppler C, Weissert D, Kappe E, et al.: Osteosarcoma of the penile
tate cancer risk, recurrence, and survival: a systematic review by the bone (os penis) in a dog, Aust Vet J 87:52–55, 2009.
european association of urology section of oncological urology, Eur 289. Webb JA, Liptak JM, Hewitt SA, et al.: Multilobular osteochon-
Urol Focus, 2018, epub ahead of print. https://doi.org/10.1016/j. drosarcoma of the os penis in a dog, Can Vet J 50:81–84, 2009.
euf.2018.04.001. 290. Bleier T, Lewitschek HP, Reinacher M: Canine osteosarcoma
269. Anidjar M, Villette JM, Devauchelle P, et al.: In vivo model mim- of the penile bone, J Vet Med A Physiol Pathol Clin Med 50:
icking natural history of dog prostate cancer using DPC-1, a new 397–398, 2003.
canine prostate carcinoma cell line, Prostate 46:2–10, 2001. 291. Mirkovic TK, Shmon CL, Allen AL: Urinary obstruction second-
270. Kishan AU, Shaikh T, Wang PC, et al.: Clinical outcomes for ary to an ossifying fibroma of the os penis in a dog, J Am An Hosp
patients with Gleason score 9-10 prostate adenocarcinoma treated Assoc 40:152–156, 2004.
with radiotherapy or radical prostatectomy: a multi-institutional 292. Root-Kustritz MV, Fick JL, Theriogenologists ACo: Theriogenol-
comparative analysis, Eur Urol 71:766–773, 2017. ogy question of the month. Neoplasia of the os penis, J Am Vet Med
271. Kishan AU, Cook RR, Ciezki JP, et al.: Radical prostatectomy, Assoc 230:197–198, 2007.
external beam radiotherapy, or external beam radiotherapy with 293. Patnaik AK: Canine extraskeletal osteosarcoma and chondrosar-
brachytherapy boost and disease progression and mortality in coma: a clinicopathologic study of 14 cases, Vet Pathol 27:46–55,
patients with Gleason score 9-10 prostate cancer, J Am Med Assoc 1990.
319:896–905, 2018. 294. Rogers KS, Walker MA, Dillon HB: Transmissible venereal
272. Ploussard G: Robotic surgery in urology: facts and reality. What tumor: a retrospective study of 29 cases, J Am An Hosp Assoc 34:
are the real advantages of robotic approaches for prostate cancer 463–470, 1998.
patients? Curr Opin Urol 28:153–158, 2018. 295. Thrall DE: Orthovoltage radiotherapy of canine transmissible vene-
273. Ilic D, Evans SM, Allan CA, et al.: Laparoscopic and robotic- real tumors, Vet Radiol 23:217–219, 1982.
assisted versus open radical prostatectomy for the treatment of 296. Milks HJ: Some diseases of the genito-urinary system, Cornell Vet
localised prostate cancer, Cochrane Database Syst Rev 9:CD009625, 29:105–114, 1939.
2017. 297. Trabulsi EJ, Gomella LG: Cancer of the urethra and penis. In
274. Huang X, Wang L, Zheng X, et al.: Comparison of perioperative, DeVita VT, Lawrence TS, Rosenberg SA, editors: Cancer: principles
functional, and oncologic outcomes between standard laparoscopic & practice of oncology, ed 10, Philadelphia, 2015, Wolters Kluwer.
and robotic-assisted radical prostatectomy: a systemic review and 298. Yeole BB, Jussawalla DJ: Descriptive epidemiology of the cancers
meta-analysis, Surg Endosc 31:1045–1060, 2017. of male genital organs in greater Bombay, Indian J Cancer 34:
275. Phak JH, Kim HJ, Kim WC: Prostate-specific antigen kinetics fol- 30–39, 1997.
lowing hypofractionated stereotactic body radiotherapy boost as 299. Maden C, Sherman KJ, Beckman AM, et al.: History of circum-
post-external beam radiotherapy versus conventionally fractionated cision, medical conditions, and sexual activity and risk of penile
external beam radiotherapy for localized prostate cancer, Prostate cancer, J Natl Cancer Inst 85:19–24, 1993.
Int 4:25–29, 2016. 300. Hanash KA, Furlow WL, Utz DC, et al.: Carcinoma of the penis: a
276. Anwar M, Weinberg V, Chang AJ, et al.: Hypofractionated SBRT clinicopathologic study, J Urol 104:291–297, 1970.
versus conventionally fractionated EBRT for prostate cancer: com- 301. Shabbir M, Minhas S, Muneer A: Diagnosis and management of
parison of PSA slope and nadir, Radiat Oncol 9:42, 2014. premalignant penile lesions, Ther Adv Urol 3:151–158, 2011.
277. Gordon JA, Buonerba C, Pond G, et al.: Statin use and survival in 302. Harish K, Ravi R: The role of tobacco in penile carcinoma, Br J
patients with metastatic castration-resistant prostate cancer treated Urol 75:375–377, 1995.
with abiraterone or enzalutamide after docetaxel failure: the inter- 303. Backes DM, Kurman RJ, Pimenta JM, et al.: Systematic review of
national retrospective observational STABEN study, Oncotarget human papillomavirus prevalence in invasive penile cancer, Cancer
9:19861–19873, 2018. Causes Control 20:449–557, 2009.